These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients. Fung KP; Chan KH; Ng V; Tsui PT; You JHS Cardiovasc Drugs Ther; 2019 Jun; 33(3):331-337. PubMed ID: 30888571 [TBL] [Abstract][Full Text] [Related]
29. Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies. Kohn CG; Fermann GJ; Peacock WF; Wells PS; Baugh CW; Ashton V; Crivera C; Schein JR; Wildgoose P; Coleman CI Curr Med Res Opin; 2017 Sep; 33(9):1697-1703. PubMed ID: 28665208 [TBL] [Abstract][Full Text] [Related]
30. Safe-dose thrombolysis plus rivaroxaban for moderate and severe pulmonary embolism: drip, drug, and discharge. Sharifi M; Bay C; Schwartz F; Skrocki L Clin Cardiol; 2014 Feb; 37(2):78-82. PubMed ID: 24122947 [TBL] [Abstract][Full Text] [Related]
31. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study. Fermann GJ; Erkens PM; Prins MH; Wells PS; Pap ÁF; Lensing AW Acad Emerg Med; 2015 Mar; 22(3):299-307. PubMed ID: 25716463 [TBL] [Abstract][Full Text] [Related]
32. Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis. Kohn CG; Lyman GH; Beyer-Westendorf J; Spyropoulos AC; Bunz TJ; Baker WL; Eriksson D; Meinecke AK; Coleman CI J Natl Compr Canc Netw; 2018 May; 16(5):491-497. PubMed ID: 29752323 [No Abstract] [Full Text] [Related]
33. Reducing length of stay with the direct oral anti-coagulants in low and intermediate risk pulmonary embolism: a single center experience. Filopei J; Bondarsky EE; Ehrlich M; Islam M; Bajpayee G; Pang D; Shujaat A; Rowland J; Steiger DJ J Thromb Thrombolysis; 2020 Aug; 50(2):399-407. PubMed ID: 31997255 [TBL] [Abstract][Full Text] [Related]
34. Practical management of rivaroxaban for the treatment of venous thromboembolism. Imberti D; Benedetti R Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396 [TBL] [Abstract][Full Text] [Related]
35. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Beyer-Westendorf J; Schellong SM; Gerlach H; Rabe E; Weitz JI; Jersemann K; Sahin K; Bauersachs R; Lancet Haematol; 2017 Mar; 4(3):e105-e113. PubMed ID: 28219692 [TBL] [Abstract][Full Text] [Related]
36. Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. Greenberg B; Neaton JD; Anker SD; Byra WM; Cleland JGF; Deng H; Fu M; La Police DA; Lam CSP; Mehra MR; Nessel CC; Spiro TE; van Veldhuisen DJ; Vanden Boom CM; Zannad F JAMA Cardiol; 2019 Jun; 4(6):515-523. PubMed ID: 31017637 [TBL] [Abstract][Full Text] [Related]
37. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients. Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320 [TBL] [Abstract][Full Text] [Related]
38. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial. Yhim HY; Choi WI; Kim SH; Nam SH; Kim KH; Mun YC; Oh D; Hwang HG; Lee KW; Song EK; Kwon YS; Bang SM Korean J Intern Med; 2019 Sep; 34(5):1125-1135. PubMed ID: 29788694 [TBL] [Abstract][Full Text] [Related]
39. Rivaroxaban program for acute venous thromboembolism upon ED discharge, with focus on utility of commercially available dose pack. Chu A; Limberg J Am J Emerg Med; 2017 Dec; 35(12):1910-1914. PubMed ID: 28869100 [TBL] [Abstract][Full Text] [Related]